The prevalence of Metabolic Syndrome in general population is 24% and in untreated patients with Schizophrenia 37%. Patients with schizophrenia or bipolar disorders tend to be obese or have type-2 diabetes even before the administration of antipsychotics. Moreover, conventional antipsychotics and some atypical antipsychotics increase the trend for obesity or type-2 diabetes, because of their adverse effect on glucose and lipid metabolism.
Today, accumulated knowledge and advances in pharmacology permit safe and effective treatment of psychosis, related with improvement in several clinically significant health factors (beneficial effects on metabolic parameters and body weight). This could significantly reduce the prevalence of Metabolic Syndrome in patients with schizophrenia or bipolar disorders and consequently may diminish the associated Cardiovascular Disease risk. <supplement> <title> <p>International Society on Brain and Behaviour: 2nd International Congress on Brain and Behaviour</p> </title> <note>Meeting abstracts -A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1744-859X-5-S1-full.pdf">here</a>.</note> </supplement> 
